Irinotecan Injection
96 interactions 769 cited referencesIrinotecan is used alone or in combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells. Read the full Irinotecan Injection drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Irinotecan Injection Telithromycin Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Teriflunomide Aubagio Increased exposure of BCRP substrate Details Irinotecan Injection Troleandomycin Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Tucatinib Tukysa Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Vadadustat Vafseo Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effect Details Irinotecan Injection Vimseltinib Romvimza Increased risk of BCRP substrate exposure Details Irinotecan Injection Voriconazole Vfend Increased irinotecan exposure and an increased irinotecan active metabolite exposure DetailsModerate
Irinotecan Injection Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Irinotecan Injection Citalopram Celexa An increased risk of myopathy or rhabdomyolysis Details Irinotecan Injection Encorafenib Braftovi Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Irinotecan Injection Kratom Increased CYP3A substrate exposure Details Irinotecan Injection Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Irinotecan Injection Oteseconazole Increased exposure to BCRP substrates Details Irinotecan Injection Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Irinotecan Injection Rolapitant Varubi Increased irinotecan exposure Details Irinotecan Injection Zongertinib Hernexeos Increased BCRP substrates exposure and an increased risk of BCRP substrates-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist